AU2016373365B2 - Transposon system, kit comprising the same, and uses thereof - Google Patents

Transposon system, kit comprising the same, and uses thereof Download PDF

Info

Publication number
AU2016373365B2
AU2016373365B2 AU2016373365A AU2016373365A AU2016373365B2 AU 2016373365 B2 AU2016373365 B2 AU 2016373365B2 AU 2016373365 A AU2016373365 A AU 2016373365A AU 2016373365 A AU2016373365 A AU 2016373365A AU 2016373365 B2 AU2016373365 B2 AU 2016373365B2
Authority
AU
Australia
Prior art keywords
promoter
cell
vector
exogenous dna
dna sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016373365A
Other languages
English (en)
Other versions
AU2016373365A1 (en
Inventor
Sareina Chiung-Yuan WU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genomefrontier Therapeutics Tw Co Ltd
Original Assignee
Genomefrontier Therapeutics Tw Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomefrontier Therapeutics Tw Co Ltd filed Critical Genomefrontier Therapeutics Tw Co Ltd
Publication of AU2016373365A1 publication Critical patent/AU2016373365A1/en
Assigned to GenomeFrontier Therapeutics, Inc. reassignment GenomeFrontier Therapeutics, Inc. Request for Assignment Assignors: GenomeFrontier Therapeutics, Inc.
Application granted granted Critical
Publication of AU2016373365B2 publication Critical patent/AU2016373365B2/en
Assigned to GenomeFrontier Therapeutics TW Co., Ltd. reassignment GenomeFrontier Therapeutics TW Co., Ltd. Request to Amend Deed and Register Assignors: GenomeFrontier Therapeutics, Inc.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2016373365A 2015-12-14 2016-12-12 Transposon system, kit comprising the same, and uses thereof Active AU2016373365B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562267270P 2015-12-14 2015-12-14
US62/267,270 2015-12-14
PCT/CN2016/109510 WO2017101749A1 (en) 2015-12-14 2016-12-12 Transposon system, kit comprising the same, and uses thereof

Publications (2)

Publication Number Publication Date
AU2016373365A1 AU2016373365A1 (en) 2018-05-17
AU2016373365B2 true AU2016373365B2 (en) 2021-07-08

Family

ID=59055731

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016373365A Active AU2016373365B2 (en) 2015-12-14 2016-12-12 Transposon system, kit comprising the same, and uses thereof

Country Status (11)

Country Link
US (1) US11345926B2 (enExample)
JP (1) JP6956416B2 (enExample)
KR (1) KR102249982B1 (enExample)
CN (1) CN108474005B (enExample)
AU (1) AU2016373365B2 (enExample)
CA (1) CA3004665C (enExample)
MX (1) MX380289B (enExample)
MY (1) MY184126A (enExample)
NZ (1) NZ742068A (enExample)
TW (1) TWI609960B (enExample)
WO (1) WO2017101749A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
KR102523318B1 (ko) 2016-12-16 2023-04-18 비-모젠 바이오테크놀로지스, 인크. 증진된 ｈＡＴ 패밀리 트랜스포존 매개 유전자 전달 및 연관된 조성물, 시스템, 및 방법
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
EP3810764A2 (en) 2018-06-21 2021-04-28 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
US20220042038A1 (en) * 2018-12-20 2022-02-10 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
AU2020290790A1 (en) * 2019-06-11 2022-01-27 Universitat Pompeu Fabra Targeted gene editing constructs and methods of using the same
JP7693253B2 (ja) * 2021-07-09 2025-06-17 ネオジェンティーシ― コーポレーション トランスポゾンシステムおよびその用途
WO2023060589A1 (zh) * 2021-10-15 2023-04-20 深圳市深研生物科技有限公司 多转座子系统

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150283267A1 (en) * 2012-10-26 2015-10-08 Vrije Universiteit Brussel Vectors for Liver-Directed Gene Therapy of Hemophilia and Methods and Use Thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962810B2 (en) 2000-10-31 2005-11-08 University Of Notre Dame Du Lac Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac
US20100154070A1 (en) * 2005-05-14 2010-06-17 Tian Xu PiggyBac as a Tool for Genetic Manipulation and Analysis in Vertebrates
US20090042297A1 (en) * 2007-06-01 2009-02-12 George Jr Alfred L Piggybac transposon-based vectors and methods of nucleic acid integration
KR20080041146A (ko) * 2007-12-13 2008-05-09 푸단 유니버시티 척추동물에서의 유전자 조작 및 분석을 위한 도구로서의피기백
SG174155A1 (en) 2009-02-25 2011-10-28 Univ Johns Hopkins Piggybac transposon variants and methods of use
DE102011118018B4 (de) 2011-10-25 2017-10-26 Plasmidfactory Gmbh & Co. Kg Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen
CN102943092B (zh) 2012-11-20 2014-12-10 西北农林科技大学 一种通用型PiggyBac转座子转基因载体及其制备方法
KR20150085846A (ko) * 2012-11-20 2015-07-24 제이.알.심프롯캄패니 Tal-매개 전이 DNA 삽입방법
CN104342453A (zh) * 2013-08-06 2015-02-11 深圳先进技术研究院 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
EP3119896B1 (en) 2014-03-21 2022-03-23 The Sydney Children's Hospitals Network (Randwick and Westmead) Stable gene transfer to proliferating cells
CA3246595A1 (en) * 2014-04-09 2025-07-08 Dna Twopointo Inc Enhanced polynucleotide constructs for eukaryotic gene expression
SG11201608393TA (en) * 2014-04-10 2016-11-29 Seattle Children S Hospital Dba Seattle Children S Res Inst Transgene genetic tags and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150283267A1 (en) * 2012-10-26 2015-10-08 Vrije Universiteit Brussel Vectors for Liver-Directed Gene Therapy of Hemophilia and Methods and Use Thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Y.-J. J. MEIR, ET AL: "A versatile, highly efficient, and potentially safer piggyBac transposon system for mammalian genome manipulations", THE FASEB JOURNAL, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, & EXPERIMENTAL BIOLOGY MEETING; SAN DIEGO, CA, USA; APRIL 21 -25, 2018, vol. 27, no. 11, 1 November 2013 (2013-11-01), & EXPERIMENTAL BIOLOGY MEETING; SAN DIEGO, CA, USA; APRIL 21 -25, 2018, pages 4429 - 4443, XP055392156, ISSN: 0892-6638, DOI: 10.1096/fj.12-223586 *
YAA-JYUHN J MEIR ET AL, BMC BIOTECHNOLOGY, BIOMED CENTRAL LTD. LONDON, GB, (2011-03-30), vol. 11, no. 1, doi:10.1186/1472-6750-11-28, ISSN 1472-6750, page 28 *

Also Published As

Publication number Publication date
CA3004665A1 (en) 2017-06-22
CA3004665C (en) 2021-08-24
US11345926B2 (en) 2022-05-31
CN108474005B (zh) 2022-10-21
JP6956416B2 (ja) 2021-11-02
MY184126A (en) 2021-03-19
MX380289B (es) 2025-03-12
KR20180092989A (ko) 2018-08-20
MX2018007203A (es) 2018-11-12
KR102249982B1 (ko) 2021-05-11
NZ742068A (en) 2023-07-28
TWI609960B (zh) 2018-01-01
WO2017101749A1 (en) 2017-06-22
AU2016373365A1 (en) 2018-05-17
US20180320196A1 (en) 2018-11-08
TW201720926A (zh) 2017-06-16
JP2019503653A (ja) 2019-02-14
CN108474005A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
AU2016373365B2 (en) Transposon system, kit comprising the same, and uses thereof
JP7399866B2 (ja) ＣＡＲＴｙｒｉｎ組成物とその利用方法
KR102724029B1 (ko) 포유동물 세포의 특성을 변경하기 위한 인공 마이크로-rna 및 이들 생성물의 조성물을 사용한 포유동물 세포의 변형
JP6684782B2 (ja) キメラ抗原受容体
US20190241910A1 (en) Genome edited immune effector cells
EP3359676B1 (en) Transposon system, kit comprising the same, and uses thereof
KR20210021473A (ko) 푸소솜 조성물 및 그의 용도
JP2023521663A (ja) 標的化脂質粒子及び組成物ならびにその使用
KR20230029603A (ko) 필수 유전자 녹-인에 의한 선택
KR20190130608A (ko) 면역종양학을 위한 조성물 및 방법
CN111909966B (zh) 一种制备经修饰的免疫细胞的方法
KR20220038362A (ko) 재조합 ad35 벡터 및 관련 유전자 요법 개선
KR20230160885A (ko) T 림프구에서 효율적인 tcr 유전자 편집
KR20230002681A (ko) 대형 아데노바이러스 페이로드의 통합
US20250228940A1 (en) Compositions and methods for efficient and stable genetic modification of eukaryotic cells
US20230140346A1 (en) Promoter Sequences for In Vitro and In Vivo Expression of Gene Therapy Products in CD3+ Cells
WO2025156492A1 (zh) 转座酶及其用途
JP2025514304A (ja) 遺伝子治療法のための組織特異的遺伝子外セーフハーバーの同定
WO2025111340A1 (en) Engineered extrachromosomal nucleic acids and methods of use thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: GENOMEFRONTIER THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): GENOMEFRONTIER THERAPEUTICS, INC.

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: GENOMEFRONTIER THERAPEUTICS TW CO., LTD.

Free format text: FORMER NAME(S): GENOMEFRONTIER THERAPEUTICS, INC.